Neupulse, a neurotherapeutics company developing a wristband to manage the symptoms of Tourette Syndrome, has raised £3m in new funding.
The round was led by Eos Advisory and the Midlands Engine Investment Fund II, through appointed fund manager Mercia Ventures, with participation from existing and new investors. The funding will help the Nottingham-based company to scale sales and accelerate its path to market.
Neupulse’s product is designed to address critical gaps in current treatment options. The company first secured funding from the Midlands Engine Investment Fund II in 2024. The latest round enables it to move from development towards commercial launch in mid-2026, while continuing to build the evidence base required by clinicians, regulators and healthcare systems.
Paul Cable, CEO, Neupulse said: “This investment underlines the unmet need in providing people with conditions like Tourette Syndrome a solution to manage their condition, and as a company, we are driven to improve the lives of individuals with these conditions.”
Ian Rhodes, Chair of the board at Neupulse, added: “This is a great example of advanced biomedical research from a leading UK university creating an initial UK market launch during 2026. This will increasingly benefit the UK economy as the technology scales out globally.”
David Tindall, Senior Investment Manager at the British Business Bank, said: “Neupulse’s growth over the past year, following investment from the Midlands Engine Investment Fund II, has been impressive. By addressing a clear gap in the market and delivering a much-needed solution for those affected, the business exemplifies the Fund’s commitment to backing ambitious, high-growth companies. This latest round of funding will further support Neupulse in developing and launching new treatment options.”
Andrew McNeill, Investor Director at Eos, said: “We are delighted to support the next chapter of Neupulse as they move towards commercialisation. This is exactly the kind of company and science we like to back. Passionate founders and technology with the potential to positively impact the lives of people across the globe.”
Sandy Reid, Fund Principal, Mercia Ventures added: “Tourette Syndrome is believed to affect up to two per cent of all children worldwide but currently the only treatments are medication and behavioural therapy, neither of which are ideal solutions. Neupulse’s device offers a genuine alternative that could transform lives.”
The £400m Midlands Engine Investment Fund II covers the entire Midlands region and provides debt finance from £25k to £2m and equity investment up to £5m to help a range of small and medium sized businesses to start up, scale up or stay ahead. The purpose of the Midlands Engine Investment Fund II is to drive sustainable economic growth by supporting innovation and creating local opportunity for new and growing businesses across the Midlands. The Midlands Engine Investment Fund II will increase the supply and diversity of early-stage finance for smaller businesses in the Midlands, providing funds to firms that might otherwise not receive investment and help to break down barriers in access to finance.